vs
Side-by-side financial comparison of BALCHEM CORP (BCPC) and FIRST INTERSTATE BANCSYSTEM INC (FIBK). Click either name above to swap in a different company.
FIRST INTERSTATE BANCSYSTEM INC is the larger business by last-quarter revenue ($313.0M vs $263.6M, roughly 1.2× BALCHEM CORP). FIRST INTERSTATE BANCSYSTEM INC runs the higher net margin — 34.8% vs 14.9%, a 19.9% gap on every dollar of revenue. On growth, FIRST INTERSTATE BANCSYSTEM INC posted the faster year-over-year revenue change (19.8% vs 9.8%). Over the past eight quarters, FIRST INTERSTATE BANCSYSTEM INC's revenue compounded faster (13.7% CAGR vs 4.9%).
Balchem Corp is a global specialty chemicals and nutritional ingredients provider that develops, manufactures and distributes application-specific products for human nutrition, animal health, pharmaceutical and industrial end markets, serving customers across North America, Europe and Asia Pacific.
First Interstate BancSystem, Inc. is a financial holding company headquartered in Billings, Montana. It is the parent company of First Interstate Bank, a community bank with locations throughout 14 states within the Western and Midwestern United States. It is the largest bank based in Montana, as measured by total assets.
BCPC vs FIBK — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $263.6M | $313.0M |
| Net Profit | $39.2M | $108.8M |
| Gross Margin | 35.6% | — |
| Operating Margin | 19.8% | 44.5% |
| Net Margin | 14.9% | 34.8% |
| Revenue YoY | 9.8% | 19.8% |
| Net Profit YoY | 16.8% | 108.8% |
| EPS (diluted) | $1.21 | $1.07 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $263.6M | $313.0M | ||
| Q3 25 | $267.6M | $250.5M | ||
| Q2 25 | $255.5M | $248.3M | ||
| Q1 25 | $250.5M | $247.0M | ||
| Q4 24 | $240.0M | $261.3M | ||
| Q3 24 | $239.9M | $251.9M | ||
| Q2 24 | $234.1M | $244.3M | ||
| Q1 24 | $239.7M | $242.2M |
| Q4 25 | $39.2M | $108.8M | ||
| Q3 25 | $40.3M | $71.4M | ||
| Q2 25 | $38.3M | $71.7M | ||
| Q1 25 | $37.1M | $50.2M | ||
| Q4 24 | $33.6M | $52.1M | ||
| Q3 24 | $33.8M | $55.5M | ||
| Q2 24 | $32.1M | $60.0M | ||
| Q1 24 | $29.0M | $58.4M |
| Q4 25 | 35.6% | — | ||
| Q3 25 | 35.7% | — | ||
| Q2 25 | 36.4% | — | ||
| Q1 25 | 35.2% | — | ||
| Q4 24 | 36.0% | — | ||
| Q3 24 | 35.6% | — | ||
| Q2 24 | 35.5% | — | ||
| Q1 24 | 34.0% | — |
| Q4 25 | 19.8% | 44.5% | ||
| Q3 25 | 20.4% | 37.0% | ||
| Q2 25 | 20.1% | 37.7% | ||
| Q1 25 | 20.4% | 26.9% | ||
| Q4 24 | 19.8% | 25.5% | ||
| Q3 24 | 20.0% | 28.9% | ||
| Q2 24 | 19.6% | 32.1% | ||
| Q1 24 | 17.4% | 31.7% |
| Q4 25 | 14.9% | 34.8% | ||
| Q3 25 | 15.1% | 28.5% | ||
| Q2 25 | 15.0% | 28.9% | ||
| Q1 25 | 14.8% | 20.3% | ||
| Q4 24 | 14.0% | 19.9% | ||
| Q3 24 | 14.1% | 22.0% | ||
| Q2 24 | 13.7% | 24.6% | ||
| Q1 24 | 12.1% | 24.1% |
| Q4 25 | $1.21 | $1.07 | ||
| Q3 25 | $1.24 | $0.69 | ||
| Q2 25 | $1.17 | $0.69 | ||
| Q1 25 | $1.13 | $0.49 | ||
| Q4 24 | $1.03 | $0.50 | ||
| Q3 24 | $1.03 | $0.54 | ||
| Q2 24 | $0.98 | $0.58 | ||
| Q1 24 | $0.89 | $0.57 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $74.6M | — |
| Total DebtLower is stronger | — | $146.3M |
| Stockholders' EquityBook value | $1.3B | $3.4B |
| Total Assets | $1.7B | $26.6B |
| Debt / EquityLower = less leverage | — | 0.04× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $74.6M | — | ||
| Q3 25 | $65.1M | — | ||
| Q2 25 | $65.4M | — | ||
| Q1 25 | $49.9M | — | ||
| Q4 24 | $49.5M | — | ||
| Q3 24 | $73.7M | — | ||
| Q2 24 | $63.7M | — | ||
| Q1 24 | $60.3M | — |
| Q4 25 | — | $146.3M | ||
| Q3 25 | — | $146.2M | ||
| Q2 25 | — | $252.0M | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $132.2M | ||
| Q3 24 | — | $137.3M | ||
| Q2 24 | — | $383.4M | ||
| Q1 24 | — | $370.8M |
| Q4 25 | $1.3B | $3.4B | ||
| Q3 25 | $1.3B | $3.4B | ||
| Q2 25 | $1.3B | $3.4B | ||
| Q1 25 | $1.2B | $3.4B | ||
| Q4 24 | $1.1B | $3.3B | ||
| Q3 24 | $1.2B | $3.4B | ||
| Q2 24 | $1.1B | $3.2B | ||
| Q1 24 | $1.1B | $3.2B |
| Q4 25 | $1.7B | $26.6B | ||
| Q3 25 | $1.7B | $27.3B | ||
| Q2 25 | $1.7B | $27.6B | ||
| Q1 25 | $1.6B | $28.3B | ||
| Q4 24 | $1.6B | $29.1B | ||
| Q3 24 | $1.6B | $29.6B | ||
| Q2 24 | $1.6B | $30.3B | ||
| Q1 24 | $1.6B | $30.1B |
| Q4 25 | — | 0.04× | ||
| Q3 25 | — | 0.04× | ||
| Q2 25 | — | 0.07× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.04× | ||
| Q3 24 | — | 0.04× | ||
| Q2 24 | — | 0.12× | ||
| Q1 24 | — | 0.12× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $67.3M | $305.6M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | 1.72× | 2.81× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $67.3M | $305.6M | ||
| Q3 25 | $65.6M | $91.7M | ||
| Q2 25 | $47.3M | $68.1M | ||
| Q1 25 | $36.5M | $78.5M | ||
| Q4 24 | $52.3M | $355.0M | ||
| Q3 24 | $51.3M | $89.9M | ||
| Q2 24 | $45.0M | $82.3M | ||
| Q1 24 | $33.4M | $87.6M |
| Q4 25 | 1.72× | 2.81× | ||
| Q3 25 | 1.63× | 1.28× | ||
| Q2 25 | 1.23× | 0.95× | ||
| Q1 25 | 0.98× | 1.56× | ||
| Q4 24 | 1.56× | 6.81× | ||
| Q3 24 | 1.52× | 1.62× | ||
| Q2 24 | 1.40× | 1.37× | ||
| Q1 24 | 1.15× | 1.50× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BCPC
| Human Nutrition And Health | $166.1M | 63% |
| Animal Nutrition And Health | $61.2M | 23% |
| Specialty Products | $34.8M | 13% |
FIBK
Segment breakdown not available.
